Publishing options:
CRKN institutes affiliated corresponding authors
1. How do we determine eligibility of the article for the CRKN agreement?

- The submission date of the article should be on or after January 1, 2021
- The corresponding author must be affiliated with participating in the CRKN agreement
- The article must be from a participating journal

2. Why do we use submission date as the eligibility criteria?

- The submission date is the only stable point the publishing process; acceptance and publication dates vary based on the journal processes
- The author controls the submission date. This gives the author not just control, but also transparency and predictability regardless of how long or short the journal the review and publication process runs
3. Role of the institutional librarian in the Elsevier OA Platform (EOAP)

• By the time the article is in your EOAP, we have published the first version of the article in ScienceDirect (within 48 hours of acceptance)

• You therefore do not approve the publication of the article, you validate whether the corresponding author can make use of the discount under the agreement

• As a librarian, you have full rights to decide whether the author is eligible for the agreement
Corresponding author receives an email post acceptance with a unique link to complete the author journey and choose publishing options.

Authors clicks on the ‘Complete the Rights and Access information form’
Corresponding author selects his/her affiliation details which we use to identify the authors and match them to the CRKN agreement.
Corresponding author also adds the co-author affiliation details.
Author can add the Funder details. Funder can be the affiliated institute or a different one. In this case Milliman, United States is the Funder.
• Based on the corresponding author affiliation details, the author sees the Publishing Options. Subscription is followed by Gold OA option and we make it clear that author receives a 20% discount on the APC for Gold OA upon validation.

• If the librarian at the consortium rejects the author request in the Elsevier Platform, we make it clear that the author will receive a full price invoice but will also be presented with the option to change to subscription.

• Author selects Gold OA.

Subscription

- Publish as a subscription article

As a corresponding author affiliated with a Canadian institution, I will publish my article under the subscription model, making my final published article immediately available to subscribers.

Elsevier’s sharing policy explains how I can share my accepted manuscript.

Gold Open Access

- Publish as an Open Access article

Make my published article available to everyone.

As an author affiliated with a Canadian institution, upon validation, I will receive a 20% discount on the APC as part of agreement between Canadian Research Knowledge Network (CRKN) and Elsevier. I will receive an invoice to pay the remainder of the APC.

I and others can share and reuse my article in the ways described by the user license I select.

Article Publishing Charge (APC)

Price

USD 3,750.00

Institutional agreement discount

- 750.00

Full price

3,000.00

Note: If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 3,750.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact Researcher Support to publish free of charge under the Subscription model.

CRKN and Elsevier Agreement
Elsevier offers two CC licenses

Author selects CC BY NC ND in this case
Author selects the rights
System presents author with the Journal License Publishing Agreement

Your Status

- I am one author signing on behalf of all co-authors of the manuscript

License of Publishing Rights

I hereby grant to Elsevier B.V. an exclusive publishing and distribution license in the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the “Article”) in print, electronic and all other media (whether now known or later developed), in any form, in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication. This license includes the right to enforce the rights granted hereunder against third parties.

Supplemental Materials

“Supplemental Materials” shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

With respect to any Supplemental Materials that I submit, Elsevier B.V. shall have a perpetual worldwide non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials in all forms and media (whether now known or later developed) and permit others to do so. The publisher shall apply the same end user license to the Supplemental Materials as to the Article where it publishes the Supplemental Materials with the Article in the Journal on its online platforms on an Open Access basis.

Research Data

“Research Data” shall mean the result of observations or experimentation that validate research findings and that are published separate to the Article, which can include but are not limited to raw data, processed data, software, algorithms, protocols, and methods.

With respect to any Research Data that I wish to make accessible on a site or through a service of Elsevier B.V., Elsevier B.V. shall have a perpetual worldwide, non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Research Data in all forms and media (whether now known or later developed), and to permit others to do so. Where I have selected a specific end user license under which the Research Data is to be made available on a site or through a service, the publisher shall apply that end user license to the Research Data on that site or service.
Author agrees to the Journal License Publishing Agreement

Author representations

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other Journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libelous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses and, if any or any of my co-authors’ institutions has a policy that might restrict my ability to grant the rights required by this License Agreement (taking into account the Scholarly communication rights permitted hereunder), a written waiver of that policy has been obtained.
- If I and/or any of my co-authors reside in Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher’s policies relating to the use of such images or personal information. See https://www.elsevier.com/about/our-business/policies/patient-consent for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier B.V. ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see https://www.elsevier.com/copyright.

I have read and agree to the terms of the License Agreement.

7 April 2021

Copyright license v5/2017
Authors chooses to send the invoice to the organization billing details
Authors chooses to send the invoice to the organization billing details.
Author can add the VAT number, Tax exemption details. PO number is mandatory.
This is the summary page explaining the choices the author made in the publishing journey.

The authors can view also the billing address they added. This will also appear in the EOAP when the admin validates the discount request.
Once the author clicks on order and pay:

- Corresponding author and coauthors receive a copy of summary via email
- Articles becomes OA on ScienceDirect within 24 hours
- Librarian at the institute will receive a notification for validation within 48 hours who then has 3 weeks to validate the request
- If the librarian approves the request, the author will receive the discounted invoice
- If the librarian rejects the request, the author will receive the full price invoice
Support for authors and librarians

- Author queries – support@elsevier.com

- Librarian queries, EOAP account set up or changes – agreementactivation@elsevier.com

- Author journey videos: https://service.elsevier.com/app/answers/detail/a_id/29789/supporthub/publishing/track/APN2ZgoIDv8a~RNiGvwa~yKgpv0qOS75Mv9e~zj~PP_X/
Thank you